The shadow of generic rivalry has long loomed around copyright’s iconic drug, Viagra, sparking questions about the prospects of related drug portfolios. While first times saw significant profits, the intellectual property end has allowed the way for less expensive substitutes, potentially diminishing profitability and presenting a genuine hazard